Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors

Cover Page

Cite item

Full Text

Abstract

Cardioncology has emerged as a new field at the intersection of cardiology and oncology. Despite the fact that improving efficiency of antitumor treatment increased the survival of oncological hematological patients, the long-term cardiovascular consequences of this treatment have become more clinically significant.

Despite the effectiveness of modern methods of treatment, some drugs, such as Bcr-Abl kinase inhibitors, anthracyclines, HER2/Erbb2 inhibitors, vascular endothelial growth factor inhibitors, fluoropyrimidines, as well as radiation therapy can have a pronounced effect on the cardiovascular system. These toxic effects lead to cardiac arrhythmia, heart failure, vascular toxicity and even death. It is important for hematologists, oncologists and cardiologists to understand the basic diagnostic and treatment strategies that should be used in the event of toxicity of this kind. At a time when, due to the developed cardiotoxicity, antitumor therapy should be discontinued, in some cases, it is possible to consider continuing treatment with caution and careful monitoring.

About the authors

L. M. Kogoniya

M.F. Vladimirsky Moscow Regional Research Clinical Institute

ORCID iD: 0000-0003-3326-4961

Build. 1, 61 / 2 Shchepkina St., Moscow 129110.

Russian Federation

M. O. Rusanov

M.F. Vladimirsky Moscow Regional Research Clinical Institute

Author for correspondence.
Email: max-rusanov@ya.ru
ORCID iD: 0000-0002-9101-8606

Maksim O. Rusanov.

Build. 1, 61 / 2 Shchepkina St., Moscow 129110.

Russian Federation

V. E. Shikina

M.F. Vladimirsky Moscow Regional Research Clinical Institute

ORCID iD: 0000-0002-6672-4269

Build. 1, 61 / 2 Shchepkina St., Moscow 129110.

Russian Federation

References

  1. Moslehi J.J., Salem J.E., Sosman J.A. et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018;391(10124):933. doi: 10.1016/S0140-6736(18)30533-6
  2. Lin L., Yan L., Liu Y. et al. Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study. J Hematol Oncol 2019;12(1):96. doi: 10.1186/s13045-019-0783-9
  3. Cardinale D., Colombo A., Bacchiani G. et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131(22):1981-8. doi: 10.1161/CIRCULATIONAHA.114.013777
  4. Johnson D.B., Balko J.M., Compton M.L. et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375(18):1749-55. doi: 10.1056/NEJMoa1609214
  5. Vitsenya M.V., Ageev F.T., Gilyarov M.Yu. et al. Practical guidelines for the correction of cardiovascular toxicity of antitumor therapy. Zlokachestvennye opukholi: Prakticheskie rekommendatsii RUSSCO = Malignant Tumors: RUSSCO Practical Guidelines 2021;11(3s2):78-98. (In Russ.). doi: 10.18027/2224-5057-2021-11-3s2-41
  6. Lancellotti P., Suter T.M., Lopez-Fernandez T. et al. Cardio-oncology services: rationale, organization, and implementation. Eur Heart J 2019;40(22):1756-63. doi: 10.1093/eurheartj/ehy453
  7. Yancy C.W., Jessup M., Bozkurt B. et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines. Circulation 2013;128(16):1810-52. doi: 10.1161/CIR.0b013e31829e8807
  8. Seidman A., Hudis C., Pierri M.K. et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20(5):1215-21. doi: 10.1200/JCO.2002.20.5.1215
  9. Perez I.E., Taveras Alam S., Hernandez G.A., Sancassani R. Cancer therapy-related cardiac dysfunction: an overview for the clinician. Clin Med Insights Cardiol 2019;13:1179546819866445. doi: 10.1177/1179546819866445
  10. Von Hoff D.D., Layard M.W., Basa P. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91(5):710-7. doi: 10.7326/0003-4819-91-5-710
  11. Yeh E.T., Tong A.T., Lenihan D.J. et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109(25): 3122-31. doi: 10.1161/01.CIR.0000133187.74800.B9
  12. Volkova M., Russell R.3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011;7(4):214-20. doi: 10.2174/157340311799960645
  13. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97(11): 2869-79. doi: 10.1002/cncr.11407
  14. Chang H.M., Moudgil R., Scarabelli T. et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol 2017;70(20):2536-51. doi: 10.1016/j.jacc.2017.09.1096
  15. McGowan J.V., Chung R., Maulik A. et al. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 2017;31(1):63-75. doi: 10.1007/s10557-016-6711-0
  16. Curigliano G., Cardinale D., Suter T. et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23 Suppl 7:vii155-66. doi: 10.1093/annonc/mds293
  17. Fallah-Rad N., Walker J.R., Wassef A. et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011;57(22):2263-70. doi: 10.1016/j.jacc.2010.11.063
  18. Rosa G.M., Gigli L., Tagliasacchi M.I. et al. Update on cardiotoxicity of anticancer treatments. Eur J Clin Invest 2016; 46(3):264-84. doi: 10.1111/eci.12589
  19. Markman T.M., Ruble K., Loeb D. et al. Electrophysiological effects of anthracyclines in adult survivors of pediatric malignancy. Pediatr Blood Cancer 2017;64(11). doi: 10.1002/pbc.26556
  20. Van Dalen E.C., van der Pal H.J., Kremer L.C. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2016;3(3):CD005008. doi: 10.1002/14651858.CD005008.pub4
  21. Smith D.H., Adams J.R., Johnston S.R. et al. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann Oncol 2002;13(10): 1590-7. doi: 10.1093/annonc/mdf275
  22. Van Dalen E.C., Caron H.N., Dickinson H.O., Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008;(2):CD003917. doi: 10.1002/14651858.CD003917.pub3
  23. Bosch X., Rovira M., Sitges M. et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013;61(23):2355-62. doi: 10.1016/j.jacc.2013.02.072
  24. Schuchter L.M., Hensley M.L., Meropol N.J. et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002;20(12):2895-903. doi: 10.1200/JCO.2002.04.178
  25. Renehan A.G., Tyson M., Egger M. et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371(9612):569-78. doi: 10.1016/S0140-6736(08)60269-X
  26. Kenchaiah S., Sesso H.D., Gaziano J.M. Body mass index and vigorous physical activity and the risk of heart failure among men. Circulation 2009;119(1):44-52. doi: 10.1161/CIRCULATIONAHA.108.807289
  27. Kenchaiah S., Chesebro J.H. The epidemiologic association between obesity and heart failure. Am Coll Cardiol Ext Learn 2017;49(8):4-6.
  28. Kwakman J.J., Simkens L.H., Mol L. et al. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. Eur J Cancer 2017;76:93-9. doi: 10.1016/j.ejca.2017.02.009
  29. Li W., Croce K., Steensma D.P. et al. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol 2015;66(10):1160-78. doi: 10.1016/j.jacc.2015.07.025
  30. Mitra M.S., Donthamsetty S., White B., Mehendale H.M. High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity. Toxicol Appl Pharmacol 2008;231(3):413-22. doi: 10.1016/j.taap.2008.05.006
  31. Guenancia C., Hachet O., Aboutabl M. et al. Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity. Cancer Chemother Pharmacol 2016;77(4):777-85. doi: 10.1007/s00280-016-2995-9
  32. Bosch X., Rovira M., Sitges M. et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013;61(23):2355-62. doi: 10.1016/j.jacc.2013.02.072
  33. Majed B., Moreau T., Senouci K. et al. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat 2008;111(2):329-42. doi: 10.1007/s10549-007-9785-3
  34. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4(8):579-91. doi: 10.1038/nrc1408
  35. Slamon D., Eiermann W., Robert N. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365(14): 1273-83. doi: 10.1056/NEJMoa0910383
  36. Stenina M.B., Zhukova L.G., Koroleva I.A. et al. Practical guidelines for the drug treatment of breast cancer. Zlokachestvennye opukholi: Prakticheskie rekommendatsii RUSSCO = Malignant Tumors: RUSSCO Practical Guidelines 2020;10(3s2-1):145-82. (In Russ.). doi: 10.18027/2224-5057-2020-10-3s2-09
  37. Piepoli M.F., Hoes A.W., Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37(29): 2315-81. doi: 10.1093/eurheartj/ehw106
  38. Labianca R., Beretta G., Clerici M. et al. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982;68(6):505-10.
  39. Kabore E.G., Guenancia C., Vaz-Luis I. et al. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. PLoS Med 2019;16(12):e1002989. doi: 10.1371/journal.pmed.1002989
  40. Campia U., Moslehi J.J., Amiri-Kordes-tani L. et al. Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the american heart association. Circulation 2019;139(13):e579-602. doi: 10.1161/CIR.0000000000000641
  41. Cameron A.C., Touyz R.M., Lang N.N. Vascular complications of cancer chemotherapy. Can J Cardiol 2016;32(7):852-62. doi: 10.1016/j.cjca.2015.12.023
  42. Arnett D.K., Blumenthal R.S., Albert M.A. et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardio-logy/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140(11):e596-646. doi: 10.1161/CIR.0000000000000678
  43. Singh A.P., Glennon M.S., Umbarkar P. et al. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. Cardiovasc Res 2019;115(5):966-77. doi: 10.1093/cvr/cvz006
  44. Aichberger K.J., Herndlhofer S., Schernthaner G.H. et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86(7):533-9. doi: 10.1002/ajh.22037
  45. Hochhaus A., Baccarani M., Silver R.T. et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34(4): 966-84. doi: 10.1038/s41375-020-0776-2
  46. Zhu X., Stergiopoulos K., Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009;48(1):9-17. doi: 10.1080/02841860802314720
  47. Maitland M.L., Bakris G.L., Black H.R. et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010;102(9):596-604. doi: 10.1093/jnci/djq091
  48. Salem J.E., Manouchehri A., Moey M. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018;19(12):1579-89. doi: 10.1016/S1470-2045(18)30608-9
  49. Johnson D.B., Balko J.M., Compton M.L. et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375(18):1749-55. doi: 10.1056/NEJMoa1609214
  50. Geisler B.P., Raad R.A., Esaian D. et al. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer 2015; 3:4. doi: 10.1186/s40425-015-0048-2
  51. Anderson R.D., Brooks M. Apical takotsubo syndrome in a patient with metastatic breast carcinoma on novel immunotherapy. Int J Cardiol 2016;222:760-1. doi: 10.1016/j.ijcard.2016.07.291
  52. Heinzerling L., Ott P.A., Hodi F.S. et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 2016;4:50. doi: 10.1186/s40425-016-0152-y
  53. Ederhy S., Cautela J., Ancedy Y. et al. Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors. JACC Cardiovasc Imaging 2018;11(8):1187-90. doi: 10.1016/j.jcmg.2017.11.036
  54. Roth M.E., Muluneh B., Jensen B.C. et al. Left ventricular dysfunction after treatment with ipilimumab for metastatic melanoma. Am J Ther 2016;23(6):e1925-8. doi: 10.1097/MJT.0000000000000430
  55. Weinstock C., Khozin S., Suzman D. et al. U.S. Food and Drug Administration approval summary: atezolizumab for metastatic non-small cell lung cancer. Clin Cancer Res 2017;23(16):4534-9. doi: 10.1158/1078-0432.CCR-17-0540
  56. Nykl R., Fischer O., Vykoupil K., Taborsky M. A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior STEMI) -systemic inflammatory response syndrome after use of pembrolizumab. Arch Med Sci Atheroscler Dis 2017;2:e100-2. doi: 10.5114/amsad.2017.72531
  57. Lenneman C.G., Sawyer D.B. Cardiooncology: an update on cardiotoxicity of cancer-related treatment. Circ Res 2016;118(6):1008-20. doi: 10.1161/CIRCRESAHA.115.303633
  58. Rygiel K. Cardiotoxic effects of radiotherapy and strategies to reduce them in patients with breast cancer: an overview. J Cancer Res Ther 2017;13(2):186-92. doi: 10.4103/0973-1482.187303
  59. Niska J.R., Thorpe C.S., Allen S.M. et al. Radiation and the heart: systematic review of dosimetry and cardiac endpoints. Expert Rev Cardiovasc Ther 2018;16(12):931-50. doi: 10.1080/14779072.2018.1538785
  60. Yeboa D.N., Evans S.B. Contemporary breast radiotherapy and cardiac toxicity. Semin Radiat Oncol 2016;26(1):71-8. doi: 10.1016/j.semradonc.2015.09.003
  61. Domercant J., Polin N., Jahangir E. Cardio-oncology: a focused review of an-thracycline-, human epidermal growth factor receptor 2 inhibitor-, and radiation-induced cardiotoxicity and management. Ochsner J 2016;16(3):250-6.
  62. Adams M.J., Lipsitz S.R., Colan S.D. et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004;22(15):3139-48. doi: 10.1200/JCO.2004.09.109
  63. Lancellotti P., Nkomo V.T., Badano L.P. et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2013;14(8):721-40. doi: 10.1093/ehjci/jet123
  64. Swanson T., Grills I.S., Ye H. et al. Six-year experience routinely using moderate deep inspiration breath-hold for the reduction of cardiac dose in leftsided breast irradiation for patients with early-stage or locally advanced breast cancer. Am J Clin Oncol 2013;36(1):24-30. doi: 10.1097/COC.0b013e31823fe481
  65. Menezes K.M., Wang H., Hada M., Saganti P.B. Radiation matters of the heart: a mini review. Front Cardiovasc Med 2018;5:83. doi: 10.3389/fcvm.2018.0008
  66. Boyle J., Ackerson B., Gu L., Kelsey C.R. Dosimetric advantages of intensity modulated radiation therapy in locally advanced lung cancer. Adv Radiat Oncol 2017;2(1):6-11. doi: 10.1016/j.adro.2016.12.006
  67. Chun S.G., Hu C., Choy H. et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. J Clin Oncol 2017;35(1):56-62. doi: 10.1200/JCO.2016.69.1378

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.

The website of the journal Oncohematology contains materials intended exclusively for healthcare professionals.

By closing this message, you confirm* that you are a licensed healthcare professional or a student of a medical educational institution.

This one-time confirmation is valid for the next 30 days.